# Scott Requadt

> Scott Requadt is the founding CEO of Prolium Bioscience, a New York-based biotech that emerged from stealth in March 2026 with a $50M Series A from RTW and a Phase 1/2-ready CD20xCD3 bispecific T-cell engager, PRO-203, in-licensed from KeyMed Biosciences and InnoCare Pharma for severe autoimmune disease. A lawyer-turned-investor-turned-operator, Requadt spent a decade at Clarus Ventures (later Blackstone Life Sciences) as Managing Director, ran Talaris Therapeutics as CEO from 2018 through its 2023 wind-down, and now sits on the board of ESSA Pharmaceuticals. He trained at McGill, Toronto Law, and Harvard Business School (Baker Scholar), started his career as an M&A attorney at Davis Polk, and has spent the intervening twenty years turning that unusual pedigree into biotech deals.

- **Role:** President, CEO and Director at Prolium Bioscience
- **Organizations:** Prolium Bioscience, ESSA Pharmaceuticals (Board), Blackstone Life Sciences (Venture Partner Advisor), Clarus Ventures (former MD), Talaris Therapeutics (former CEO), TransForm Pharmaceuticals (former), Davis Polk & Wardwell (former)
- **Nationality:** Canadian
- **Education:** B.Com, Economics & Finance (First Class Honors), McGill University, J.D., University of Toronto, MBA (Baker Scholar), Harvard Business School
- **Known for:** Baker Scholar at Harvard Business School (top 5% of MBA class), First Class Honors at McGill in Economics & Finance, Led Clarus Ventures investments across therapeutics, medtech and diagnostics

## Career timeline

- **pre-2005** — M&A attorney at Davis Polk & Wardwell in New York, representing private equity, pharma and technology clients
- **pre-2005** — Director of Business Development at TransForm Pharmaceuticals, through acquisition by Johnson & Johnson
- **2005** — Joined Clarus Ventures (Cambridge, MA) as Principal
- **2010** — Promoted to Partner at Clarus Ventures
- **2015** — Promoted to Managing Director at Clarus Ventures
- **2018** — Became President, CEO and Director of Talaris Therapeutics
- **2021** — Took Talaris Therapeutics public on Nasdaq (TALS)
- **2023** — Stepped away as Talaris wound down operations
- **2025** — Prolium Bioscience founded, backed by RTW
- **2026-03** — Prolium launches publicly with $50M Series A and first patients dosed with PRO-203
- **2026-06** — First patient dosed in multinational Phase 1/2 study of PRO-203 in systemic sclerosis

## Achievements

- Baker Scholar at Harvard Business School (top 5% of MBA class)
- First Class Honors at McGill in Economics & Finance
- Led Clarus Ventures investments across therapeutics, medtech and diagnostics
- Took Talaris Therapeutics from Series A through IPO
- Founded Prolium Bioscience with $50M Series A and clinical-stage asset from launch

## Latest updates

- **2026-03** — Prolium Bioscience launches publicly with $50M Series A led by RTW and first patients dosed with PRO-203.
- **2026-06** — Announces first patient dosed in multinational Phase 1/2 study of PRO-203 in systemic sclerosis, plus last patient last visit in an investigator-led study in refractory lupus nephritis.

## Links

- Website: https://proliumbio.com
- LinkedIn: https://www.linkedin.com/in/scott-requadt-a9830392/

---

Profile page: https://yespress.io/scott-requadt
Published by YesPress — https://yespress.io
Last updated: 2026-07-08